Yasuhiro Honda, MD. Clinical Professor, Medicine - Cardiovascular Medicine. David Lee, MD. Jennifer Tremmel. Susan P. Simon H. Celina Yong. This profile is not available. Abstract Critical limb ischemia CLI is a terminal stage of peripheral arterial disease that, in the absence of intervention, may lead to lower extremity amputation or death. Endovascular interventions have become a first-line approach to the management of CLI and have advanced considerably within [ Critical limb ischemia CLI is a terminal stage of peripheral arterial disease that, in the absence of intervention, may lead to lower extremity amputation or death.
Endovascular interventions have become a first-line approach to the management of CLI and have advanced considerably within the past decade. This review summarizes the types of percutaneous devices and the techniques that are available for the management of CLI and the data supporting their use. These include devices that establish and maintain vessel patency, including percutaneous transluminal angioplasty, drug-coated balloons, bare metal stents, drug-eluting stents, bioresorbable vascular scaffolds, and atherectomy; devices that provide protection from embolization; and, cell-based therapies.
Additionally, ongoing trials with important implications for the field are discussed. Open Access Feature Paper Review. Abstract Venous disease is more common than peripheral arterial disease. Pathophysiologically, venous disease can be associated with obstruction, reflux, or both. A common feature in chronic venous disease is ambulatory venous hypertension. Inflammatory and pro-thrombotic mechanisms can be activated. The current therapies, including compression, [ Venous disease is more common than peripheral arterial disease.
The current therapies, including compression, ablation, and recanalization are discussed. Abstract Percutaneous coronary intervention PCI with stenting for the treatment of acute coronary syndrome ACS is the contemporary standard of care. The efficacy of this therapy has been [ Percutaneous coronary intervention PCI with stenting for the treatment of acute coronary syndrome ACS is the contemporary standard of care. The efficacy of this therapy has been well established but the optimal duration of DAPT remains elusive, and has thus far attracted a prodigious deal of scientific attention.
The decision regarding DAPT duration can be clinically challenging in the modern era with the evolution of newer stents, more potent antiplatelet agents, and novel anticoagulant drugs in addition to an older patient population with multiple comorbidities. The following review is aimed at critically evaluating the available evidence to help make these crucial clinical decisions regarding duration of DAPT and triple therapy.
Figure 1. Abstract The trans-venous implantable cardioverter defibrillator TV-ICD is effective in treating life-threatening ventricular arrhythmia and reduces mortality in high-risk patients. However, there are significant short- and long-term complications that are associated with intravascular leads.
Multimodality Imaging in the Cardiac Catheterization Laboratory
These shortcomings are mostly relevant in young patients with long [ The trans-venous implantable cardioverter defibrillator TV-ICD is effective in treating life-threatening ventricular arrhythmia and reduces mortality in high-risk patients. These shortcomings are mostly relevant in young patients with long life expectancy and low risk of death from non-arrhythmic causes.
Drawbacks of trans-venous leads recently led to the development of the entirely subcutaneous implantable cardioverter defibrillator S-ICD. The S-ICD does not require vascular access or permanent intravascular defibrillation leads. Therefore, it is expected to overcome many complications associated with conventional ICDs. This review highlights data on safety and efficacy of the S-ICD and is envisioned to help in identifying the role of this device in clinical practice.
The very latest advances about to be unveiled 31 August to 4 September in Paris, France
The primary sensing vector was selected by the system and approved by the physician. One year after implantation, the patient experienced an episode of ventricular fibrillation. Time to therapy was Abstract Non-surgical left atrial appendage occlusion has emerged as an alternative to anticoagulant therapy in the management of stroke risk in patients with atrial fibrillation.
This review reports on some of the more common devices that are currently being used to manage patients in [ Non-surgical left atrial appendage occlusion has emerged as an alternative to anticoagulant therapy in the management of stroke risk in patients with atrial fibrillation. This review reports on some of the more common devices that are currently being used to manage patients in this challenging group. Image reproduced with permission from Boston Scientific.
Abstract Interventional cardiologists have witnessed an explosive growth in the field. A wide array of percutaneous procedures allow us to treat numerous cardiac conditions less invasively. However, the way we work has changed very little over the past decades. We continue to stand at [ Interventional cardiologists have witnessed an explosive growth in the field. We continue to stand at the tableside for prolonged periods of time, exposing ourselves to the very real risks of radiation exposure as well as to the associated orthopedic injuries from radiation protection.
The precision of our procedures is limited by the distance from the fluoroscopic images and, furthermore, patients are potentially at risk from operator fatigue caused by a physician standing at the table for prolonged periods while wearing cumbersome radiation protection gear.
Robotic-assisted coronary intervention removes the operator from the radiation field and has been shown to markedly reduce operator exposure as well as allow for more precise positioning of balloons and stents.
Cardiovascular medicine will never be the same
Circulation ;—8. Prevalence, impact, and predictive value of detecting subclinical coronary and carotid atherosclerosis in asymptomatic adults: the BioImage study. Eur Heart J ;—7. The risk continuum of atherosclerosis and its implications for defining CHD by coronary angiography.
Atherosclerosis ;— Contrast-enhanced ultrasound: clinical applications in patients with atherosclerosis. Int J Cardiovasc Imaging ;— Emerging diagnostic and therapeutic molecular imaging applications in vascular disease. Vasc Med ;— Safety and efficacy of ultrasound-enhanced thrombolysis: a comprehensive review and meta-analysis of randomized and nonrandomized studies. Stroke ;—7. Stroke ;— Safety and efficacy of sonothrombolysis for acute ischaemic stroke: a multicentre, double-blind, phase 3, randomised controlled trial.
Lancet Neurol ;— Therapeutic arteriogenesis by ultrasound-mediated VEGF plasmid gene delivery to chronically ischemic skeletal muscle.
Circ Res ;— Comparison of gene delivery techniques for therapeutic angiogenesis ultrasound-mediated destruction of carrier microbubbles versus direct intramuscular injection. Ultrasound-microbubble-mediated intercellular adhesion molecule-1 small interfering ribonucleic acid transfection attenuates neointimal formation after arterial injury in mice.
Circulation ;— Magnetic nanoparticles in MR imaging and drug delivery. Adv Drug Deliv Rev ;— Molecular imaging of atherosclerosis with nanoparticle-based fluorinated MRI contrast agents. Nanomedicine Lond ;— Photodynamic therapy using a protease-mediated theranostic agent reduces cathepsin-B activity in mouse atheromata in vivo.
Arterioscler Thromb Vasc Biol ;—5. Gold nanorods as a theranostic platform for in vitro and in vivo imaging and photothermal therapy of inflammatory macrophages. Nanoscale ;— Targeted antiproliferative drug delivery to vascular smooth muscle cells with a magnetic resonance imaging nanoparticle contrast agent: implications for rational therapy of restenosis. Circulation ;—7. Endothelial alpha v beta3 integrin-targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis.
Arterioscler Thromb Vasc Biol ;—9. Nanoparticles for diagnosis and therapy of atherosclerosis and myocardial infarction: evolution toward prospective theranostic approaches. Theranostics ;— Molecularly engineered theranostic nanoparticles for thrombosed vessels: h2o2-activatable contrast-enhanced photoacoustic imaging and antithrombotic therapy.